ALICE B GOTTLIEB ET AL: "AB0738 - Secukinumab Reduces Hscrp Levels in Subjects with Moderate-To-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Sub-Analysis from the Phase 3 Erasure Study", ANNALS OF THE RHEUMATIC DISEASES, 1 January 2014 (2014-01-01), pages 1 - 1, XP055227757, Retrieved from the Internet <URL:http://ard.bmj.com/content/73/Suppl_2/1047.2.abstract> [retrieved on 20151111], DOI: 10.1136/annrheumdis-2014-eular.1109 (B1)

ALICE B. GOTTLIEB ET AL: "Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study", AMERICAN COLLEAGE OF RHEUMATOLOGY MEETING ABSTRACTS, 1 January 2013 (2013-01-01), pages 1 - 4, XP055227813, Retrieved from the Internet <URL:http://acrabstracts.org/abstract/secukinumab-shows-substantial-improvement-in-both-psoriasis-symptoms-and-physical-functioning-in-moderate-to-severe-plaque-psoriasis-patients-with-psoriatic-arthritis-a-subanalysis-of-a-phase-3-mult/> [retrieved on 20151111] (B1)

JOSHUA E WEITZ ET AL: "Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 14, no. 4, 1 April 2014 (2014-04-01), ASHLEY, LONDON; GB, pages 515 - 526, XP055226577, ISSN: 1471-2598, DOI: 10.1517/14712598.2014.890587 (B1)

MCINNES I ET AL: "Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial", ARTHRITIS & RHEUMATISM; 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETING, WILEY, US; CHICAGO, IL, USA, vol. 63, no. Suppl. S10, 1 January 2011 (2011-01-01), pages S306, XP008147787, ISSN: 0004-3591, [retrieved on 20111209], DOI: 10.1002/ART.33310 (B1)

PATEL DHAVALKUMAR D ET AL: "Effect of IL-17A blockade with secukinumab in autoimmune diseases", ANNALS OF THE RHEUMATIC DISEASES, B M J GROUP, GB, vol. 72, no. Suppl. 2, 1 April 2013 (2013-04-01), pages ii116 - ii123, XP009174221, ISSN: 1468-2060 (B1)

WO-A1-2013/077907 (B1)

SARAH L. GAFFEN ET AL: "The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing", THE JOURNAL OF IMMUNOLOGY, vol. 14, no. 9, 22 August 2014 (2014-08-22), GB, pages 585 - 600, XP055227747, ISSN: 1474-1733, DOI: 10.1038/nri3707 (B1)

WO-A1-2006/013107 (B1)

WO-A1-2012/045848 (B1)

WO-A1-2012/082573 (B1)

RITA BARON-FAUST: "The IL-17 Superfamily: What Future for PsA? The IL-17 Superfamily: What Future for PsA?", RHEUMATOLOGY NETWORK, 18 March 2014 (2014-03-18), pages 1 - 5, XP055227427, Retrieved from the Internet <URL:http://www.rheumatologynetwork.com/psoriatic-arthritis/il-17-superfamily-what-future-psa> [retrieved on 20151110] (B1)